News of Note—GlaxoSmithKline, Ebola and SK Bioscience

In this week's news of note, the World Health Organization declared an end to the Ebola outbreak in Congo. (Pixabay)

Here is some other vaccine news of note for the week.

> GlaxoSmithKline has reported £1.25 billion ($1.65 billion) in second-quarter vaccine sales, a 16% increase at constant currencies. Reuters story

> The World Health Organization has declared an end to the Ebola outbreak in the Democratic Republic of Congo. Release

> South Korea's SK Bioscience is spending $89 million on a plant to increase vaccine capacity. Pulse story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.